C. Perno

发表

Prediction of response to antiretroviral therapy by human experts and by the EuResist data‐driven expert system (the EVE study)

Thomas Lengauer, A. Wensing, R. Kaiser, 2010, HIV medicine.

European guidelines on the clinical management of HIV-1 tropism testing.

A. Wensing, H. Walter, R. Kaiser, 2011, The Lancet. Infectious diseases.

The prognostic value to predict virological outcomes of 14 distinct systems used to interpret the results of genotypic HIV-1 drug resistance testing in untreated patients starting their first HAART

C. Perno, A. Lepri, C. Balotta, 2004 .

Selected nucleotide sequence of the pol gene of the monocytotropic strain HIV type 1 BaL.

C. Perno, M. Clementi, S. Aquaro, 1997, AIDS research and human retroviruses.

A fuzzy relational system trained by genetic algorithms and HIV-1 resistance genotypes/virological response data from prospective studies usefully predicts treatment outcomes

G. Ulivi, L. Ruiz, M. Prosperi, 2004 .

Consensus statement of the European guidelines on clinical management of HIV-1 tropism testing

H. Walter, R. Kaiser, K. Korn, 2010, Journal of the International AIDS Society.

1,2,3-Triazole-[2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D- ribofuranosyl]-3'-spiro-5"-(4"-amino-1",2"-oxathiole 2",2"-dioxide) (TSAO) analogues: synthesis and anti-HIV-1 activity.

E. De Clercq, C. Perno, J. Balzarini, 1994, Journal of medicinal chemistry.

Respiratory viruses and influenza-like illness: a survey in the area of Rome, winter 2004-2005.

I. Donatelli, C. Perno, M. Ciotti, 2006, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

Respiratory viruses and influenza-like illness: a survey in the area of Rome, winter 2004-2005.

I. Donatelli, C. Perno, M. Ciotti, 2006, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL.

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, G. Ippolito, 2019, The Journal of antimicrobial chemotherapy.

Performance evaluation of an in-house human immunodeficiency virus type-1 protease-reverse transcriptase genotyping assay in Cameroon

C. Perno, V. Colizzi, C. Perno, 2011, Archives of Virology.

Italian Consensus Statement on Management of HIV-Infected Individuals with Advanced Disease Naïve to Antiretroviral Therapy

A. d’Arminio Monforte, A. Lazzarin, M. Clerici, 2009, Infection.

Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, G. Ippolito, 2013, The Journal of antimicrobial chemotherapy.

Improving adherence to highly active anti-retroviral therapy in Africa: the DREAM programme in Mozambique.

P. Narciso, C. Perno, S. Mancinelli, 2006, Health education research.

An ion-pairing high-performance liquid chromatographic method for the direct simultaneous determination of nucleotides, deoxynucleotides, nicotinic coenzymes, oxypurines, nucleosides, and bases in perchloric acid cell extracts.

C. Perno, B. Giardina, G. Lazzarino, 1995, Analytical biochemistry.

Effect of maraviroc on non-R5 tropic HIV-1: refined analysis of subjects from the phase IIb study A4001029.

F. Ceccherini‐Silberstein, B. Clotet, J. Martinez-Picado, 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Immunomodulatory activity of 9-(2-phosphonylmethoxyethyl)adenine (PMEA), a potent anti-HIV nucleotide analogue, on in vivo murine models.

E. De Clercq, A. Foli, C. Perno, 1991, Antiviral research.

Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort.

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, G. Ippolito, 2019, The Journal of antimicrobial chemotherapy.

HIV MDR is still a relevant issue despite its dramatic drop over the years.

Domenico Di Carlo, F. Ceccherini‐Silberstein, A. Antinori, 2020, The Journal of antimicrobial chemotherapy.

Inhibition of HIV Replication and Enhancement of Immune Functions by the Acyclic Nucleoside Phosphonate 9-(2-Phosphonyl-Methoxyethyl)Adenine (PMEA)

C. Perno, J. Balzarini, S. Aquaro, 1993 .

Different pattern of activity of inhibitors of the human immunodeficiency virus in lymphocytes and monocyte/macrophages.

A. Bergamini, E. De Clercq, R. Pauwels, 1992, Antiviral research.

Safety of nevirapine‐containing antiretroviral triple therapy regimens to prevent vertical transmission in an African cohort of HIV‐1‐infected pregnant women

P. Narciso, C. Perno, S. Mancinelli, 2006, HIV medicine.

HAART in Pregnancy: Safety, Effectiveness, and Protection from Viral Resistance: Results from the DREAM Cohort

P. Narciso, C. Perno, L. Palombi, 2005 .

Hepatitis C Virus Genetic Variability and the Presence of NS5B Resistance-Associated Mutations as Natural Polymorphisms in Selected Genotypes Could Affect the Response to NS5B Inhibitors

F. Ceccherini‐Silberstein, C. Perno, C. Mirabelli, 2014, Antimicrobial Agents and Chemotherapy.

Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients with an anti-HBc-positive donor.

Domenico Di Carlo, C. Perno, M. Andreoni, 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation-a position paper.

R. Bruno, G. Antonelli, C. Perno, 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Activity of acyclic nucleoside phosphonate analogues against human immunodeficiency virus in monocyte/macrophages and peripheral blood lymphocytes.

E. De Clercq, C. Perno, J. Balzarini, 1991, Biochemical and biophysical research communications.

Mechanism of anti-HIV action of masked alaninyl d4T-MP derivatives.

E. De Clercq, L. Naesens, C. Perno, 1996, Proceedings of the National Academy of Sciences of the United States of America.

Activity of the (R)-enantiomers of 9-(2-phosphonylmethoxypropyl)-adenine and 9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine against human immunodeficiency virus in different human cell systems.

E. De Clercq, C. Perno, J. Balzarini, 1996, Biochemical and biophysical research communications.

Potent inhibition of human immunodeficiency virus and herpes simplex virus type 1 by 9-(2-phosphonylmethoxyethyl)adenine in primary macrophages is determined by drug metabolism, nucleotide pools, and cytokines.

C. Perno, J. Balzarini, S. Aquaro, 1996, Molecular pharmacology.

Prevalence and Human Papillomavirus Infection in Italian and Immigrant Women

C. Perno, M. Ciotti, C. Perno, 2012, International journal of immunopathology and pharmacology.

Key questions in antiretroviral therapy: Italian Consensus Workshop (2005).

M. Moroni, G. Filice, R. Maserati, 2006, The Journal of antimicrobial chemotherapy.

Alarming rates of virological failure and HIV‐1 drug resistance amongst adolescents living with perinatal HIV in both urban and rural settings: evidence from the EDCTP READY‐study in Cameroon

F. Ceccherini‐Silberstein, C. Perno, V. Colizzi, 2021, HIV medicine.

Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naïve to antiviral drugs.

C. Perno, C. Perno, A. Bertoli, 2011, Antiviral research.

Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative.

R T Walker, R. T. Walker, E. De Clercq, 1989, Biochemical and biophysical research communications.

2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5''-(4''-amino-1'',2''- oxathiole-2'',2'-dioxide)pyrimidine (TSAO) nucleoside analogues: highlyselective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase.

E. De Clercq, A. Vandamme, C. Perno, 1992, Proceedings of the National Academy of Sciences of the United States of America.

Intracellular metabolism of CycloSaligenyl 3'-azido-2', 3'-dideoxythymidine monophosphate, a prodrug of 3'-azido-2', 3'-dideoxythymidine (zidovudine).

E. De Clercq, L. Naesens, C. Perno, 1999, Molecular pharmacology.

Enhancement of natural killer activity and interferon induction by different acyclic nucleoside phosphonates.

E. De Clercq, C. Perno, J. Balzarini, 1994, Antiviral research.

Efficacy of etravirine combined with darunavir or other ritonavir‐boosted protease inhibitors in HIV‐1‐infected patients: an observational study using pooled European cohort data

J. Lundgren, V. Calvez, F. Ceccherini‐Silberstein, 2015, HIV medicine.

Presence of 2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1",2"-oxath iole-2",2"-dioxide) (TSAO)-resistant virus strains in TSAO-inexperienced HIV patients.

R. Esnouf, E. De Clercq, B. Clotet, 2000, AIDS research and human retroviruses.

Red blood cells mediated delivery of 9-(2-phosphonylmethoxyethyl)adenine to primary macrophages: efficiency metabolism and activity against human immunodeficiency virus or herpes simplex virus.

S. Grimaldi, C. Perno, J. Balzarini, 1997, Antiviral research.

9-(2-Phosphonylmethoxyethyl) adenine increases the survival of influenza virus-infected mice by an enhancement of the immune system.

E. De Clercq, C. Perno, J. Balzarini, 1994, Antiviral research.

Antiretrovirus Activity of a Novel Class of Acyclic Pyrimidine Nucleoside Phosphonates

E. De Clercq, C. Pannecouque, C. Perno, 2002, Antimicrobial Agents and Chemotherapy.

Inhibition of HIV-1 Replication in Macrophages by Red Blood Cell-Mediated Delivery of a Heterodinucleotide of Azidothymidine and 9-(R)-2-(Phosphono Methoxypropyl)adenine

C. Perno, M. Magnani, L. Cappellacci, 2001, Antiviral chemistry & chemotherapy.

Snapshot on drug‐resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice

C. Perno, M. Andreoni, M. Angelico, 2013, Journal of medical virology.

Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 replication.

E. De Clercq, C. Perno, J. Balzarini, 1996, Molecular pharmacology.

Positioning of HIV-protease inhibitors in clinical practice.

C. Perno, M. Andreoni, M Andreoni, 2012, European review for medical and pharmacological sciences.

HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels.

A. Gasbarrini, F. Ceccherini‐Silberstein, V. Vullo, 2016, The Journal of antimicrobial chemotherapy.

A recent epidemiological cluster of acute hepatitis B genotype F1b infection in a restricted geographical area of Italy.

C. Perno, R. Mariani, M. Dalessandro, 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

HBsAg genetic elements critical for immune escape correlates with HBV reactivation upon immunosuppression

Y. Louzoun, C. Perno, M. Andreoni, 2014 .

Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance

C. Perno, M. Andreoni, A. Bertoli, 2011, Infection.

One year of HAART in Mozambique: survival, virological and immunological results of DREAM project in Adults and Children

P. Narciso, C. Perno, S. Mancinelli, 2004 .

Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen

Domenico Di Carlo, F. Ceccherini‐Silberstein, R. Bellagamba, 2016, The Journal of antimicrobial chemotherapy.

Targeting Nucleotide Dimers Containing Antiviral Nucleosides

C. Perno, M. Magnani, L. Cappellacci, 2005 .

Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, G. Ippolito, 2018, The Journal of antimicrobial chemotherapy.

Non-B HIV type 1 subtypes among men who have sex with men in Rome, Italy.

C. Perno, M. Ciccozzi, G. Rezza, 2009, AIDS research and human retroviruses.

Bictegravir/emtricitabine/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice.

F. Ceccherini‐Silberstein, A. Antinori, C. Perno, 2022, Journal of Global Antimicrobial Resistance.

Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, G. Ippolito, 2018, BMC Medicine.

HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia.

F. Ceccherini‐Silberstein, E. Nicastri, C. Perno, 2015, The Journal of antimicrobial chemotherapy.

Evidence of Dual Sexual Transmission of Multi-resistant HIV with Two Years Persistence of Resistance to NRTI and NNRTI: a Case Report

U. Visco-Comandini, C. Perno, C. Perno, 2008, Infection.

Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART.

H. Jessen, A. Blaxhult, V. Calvez, 2016, The Journal of antimicrobial chemotherapy.

Drug-resistant mutants of HIV-1 in patients exhibiting increasing CD4 cell count despite virological failure of highly active antiretroviral therapy.

C. Perno, A. De Luca, A. Cingolani, 2001, AIDS.

Dynamics and phylogenetic relationships of HIV-1 transmitted drug resistance according to subtype in Italy over the years 2000–14

A. Mariano, F. Ceccherini‐Silberstein, V. Vullo, 2017, The Journal of antimicrobial chemotherapy.

Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group

A. d’Arminio Monforte, F. Baldanti, F. Ceccherini‐Silberstein, 2013, Infection.

The use of human immunodeficiency virus resistance tests in clinical practice.

V. Calvez, F. Ceccherini‐Silberstein, C. Perno, 2010, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients.

F. Ceccherini‐Silberstein, P. Narciso, C. Perno, 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Phosphorylation of 9-(2-phosphonyimethoxyethyl)adenine (PMEA) is greater in macrophages than in replicating lymphocytes and fibroblasts

C. Perno, J. Balzarini, S. Aquaro, 1995 .

HUMORAL AND CELLULAR IMMUNOGENICITY and SAFETY UP TO 4 MONTHS AFTER VACCINATION WITH BNT162B2 mRNA COVID-19 VACCINE IN HEART AND LUNG TRANSPLANTED YOUNG ADULTS

P. Palma, M. L. Ciofi Degli Atti, C. Perno, 2021, medRxiv.

Mechanism of Anti-HIV Action of Masked Alaninyl 2 ,3 -Dideoxy-2 ,3 -Didehydrothymidine 5 -Monophosphate Derivatives

L. Naesens, C. Perno, J. Balzarini, 1996 .

Prevalence of mutations and determinants of genotypic resistance to etravirine (TMC125) in a large Italian resistance database (ARCA) *†

A. Antinori, M. Zazzi, C. Perno, 2010, HIV medicine.

Primary HIV-1 resistance in recently and chronically infected individuals of the Italian Cohort Naive for Antiretrovirals.

M. Moroni, G. Ippolito, A. Lazzarin, 2002, Journal of biological regulators and homeostatic agents.

Effect of Suppressing HIV Viremia on the HIV Progression of Patients Undergoing a Genotype Resistance Test after Treatment Failure

F. Ceccherini‐Silberstein, P. Narciso, V. Tozzi, 2009, Infection.